ArticleAdvances in experimental medicine and biology2022
HDL and Sepsis.
Article in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Impact of altered HDL2b/HDL3 ratio on the function of innate immune cells in sepsis.Lipids in health and disease · 2026Article
- High-density lipoprotein 2b combined with sequential organ failure assessment score as a novel prognostic indicator for sepsis patients: a prospective study.BMC infectious diseases · 2025Observational
- Relationship between preoperative neutrophil to high-density lipoprotein ratio and postoperative systemic inflammatory response syndrome in elderly patients: a retrospective cohort study.Lipids in health and disease · 2025Article
- Post-translational modifications in sepsis-induced acute kidney injury: mechanisms and perspectives.Frontiers in pharmacology · 2025Review
- High-Density Lipoprotein Predicts Intrahospital Mortality in Influenza.Journal of clinical medicine · 2024Article
- Interactions Between HDL and CD4+ T Cells: A Novel Understanding of HDL Anti-Inflammatory Properties.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Clinical biomarker profiles reveals gender differences and mortality factors in sepsis.Frontiers in immunology · 2024Article
- Consumption of Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2023Article
- HDL and LDL have distinct, opposing effects on LPS-induced brain inflammation.Lipids in health and disease · 2023Article
- Anti-inflammatory effect of ApoE23 onOpen medicine (Warsaw, Poland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis has been recognized as a global health burden in the year 2017 for its high morbidity and mortality. HDL, a cholesterol transporter, also plays vital role in inflammation besides its typical role in reverse cholesterol transportation. In septic patients, HDL levels dropped significantly. HDL exerts a variety of protective effects in the pathophysiology of sepsis including acting on pathogens, inhibiting macrophage inflammatory reaction, and modulating endothelial function in sepsis. Studies have shown that rHDL or apoA-I mimetic peptides could be therapeutic potentials in sepsis. HDL has caused increasing concern as a potential therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.